{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:17:58Z","timestamp":1792570678780,"version":"4.5.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Neurofibromatosis type 1 (NF1) is a rare genetic disorder, with lack of evidence of disease burden in China. We aimed to describe the economic burden, health-related quality of life (HRQL), and caregiver burden of NF1 patients in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted an online cross-sectional survey employing the China Cloud Platform for Rare Diseases, with 223 caregivers of NF1 pediatric patients (patients under 18), and 226 adult patients. Economic burden was estimated using direct and indirect costs related to NF1 in 2021, and the Work Productivity and Activity Impairment Questionnaire: General Health V2.0 (WPAI-GH). HRQL measures included EQ-5D-Y proxy version and PedsQL<jats:sup>\u2122<\/jats:sup> 4.0 Generic Core Scales (PedsQL GCS) proxy version for pediatric patients, and EQ-5D-5L and PedsQL<jats:sup>\u2122<\/jats:sup> 3.0 Neurofibromatosis Module (PedsQL NFM) for adult patients. Caregiver burden was estimated by Zarit Burden Interview (ZBI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For pediatric patients, the average direct cost in 2021 was CNY 33,614 (USD 4,879), and employed caregivers\u2019 annual productivity loss was 81\u2009days. EQ-5D-Y utility was 0.880\u2009\u00b1\u20090.13 and VAS score was 75.38\u2009\u00b1\u200920.67, with 52.6% patients reporting having problems in \u201cpain\/discomfort\u201d and 42.9% in \u201canxiety\/depression.\u201d PedsQL GCS total score was 68.47\u2009\u00b1\u200919.42. ZBI score demonstrated that 39.5% of caregivers had moderate-to-severe or severe burden. For adult patients, average direct cost in 2021 was CNY 24,531 (USD 3,560). Patients in employment reported an absenteeism of 8.5% and presenteeism of 21.6% according to the results of WPAI-GH. EQ-5D-5L utility was 0.843\u2009\u00b1\u20090.17 and VAS score was 72.32\u2009\u00b1\u200923.49, with more than half of patients reporting having problems in \u201cpain\/discomfort\u201d and \u201canxiety\/depression\u201d dimensions. PedsQL NFM total score was 68.40\u2009\u00b1\u200915.57.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both pediatric and adult NF1 patients in China had a wide-ranging economic burden and low HRQL, especially in the psychological dimension. Caregivers for NF1 pediatric patients experienced considerable caregiver burden. More attention and support from policymakers and stakeholders are required to relieve NF1 patients\u2019 and caregivers\u2019 distress.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1398803","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:12:30Z","timestamp":1724346750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term distress throughout one\u2019s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in China"],"prefix":"10.3389","volume":"12","author":[{"given":"Wanxian","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of neurofibromatosis 1 in German children at elementary school enrollment","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","article-title":"Incidence and mortality of neurofibromatosis: a total population study in Finland","volume":"135","author":"Uusitalo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrd3654","article-title":"Rare diseases and orphan drugs","volume":"11","author":"Melnikova","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-015-0241-x","article-title":"A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs","volume":"10","author":"Cui","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5582\/irdr.2017.01009","article-title":"Defining rare diseases in China","volume":"6","author":"Cui","year":"2017","journal-title":"Intractable Rare Dis Res"},{"key":"ref8","year":"2023"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/archdischild-2014-308084","article-title":"Annual review of children with neurofibromatosis type 1","volume":"101","author":"Dunning-Davies","year":"2016","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e20190660","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with neurofibromatosis type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","article-title":"Mortality in neurofibromatosis 1: in north West England: an assessment of actuarial survival in a region of the UK since 1989","volume":"19","author":"Evans","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/320121","article-title":"Mortality in neurofibromatosis 1: an analysis using U.S. death certificates","volume":"68","author":"Rasmussen","year":"2001","journal-title":"Am J Hum Genet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","article-title":"Epidemiology of neurofibromatosis type 1","volume":"89","author":"Friedman","year":"1999","journal-title":"Am J Med Genet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cge.12551","article-title":"Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life","volume":"88","author":"Cohen","year":"2015","journal-title":"Clin Genet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/ajmg.a.61627","article-title":"Clinical characteristics and quality of life, depression, and anxiety in adults with neurofibromatosis type 1: a nationwide study","volume":"182","author":"Doser","year":"2020","journal-title":"Am J Med Genet A"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13023-022-02195-y","article-title":"A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1","volume":"17","author":"Hamoy-Jimenez","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.gim.2021.11.024","article-title":"The rare disease neurofibromatosis 1 as a source of hereditary economic inequality: evidence from Finland","volume":"24","author":"Johansson","year":"2022","journal-title":"Genet Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40120-022-00365-5","article-title":"Burden among caregivers of pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States: a cross-sectional study","volume":"11","author":"Yang","year":"2022","journal-title":"Neurol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/SCS.0000000000006015","article-title":"Evaluation and factors of quality of life among patients with neurofibromatosis type 1-associated craniofacial plexiform neurofibromas","volume":"31","author":"Ren","year":"2020","journal-title":"J Craniofac Surg"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12874-018-0657-9","article-title":"Methods of sample size calculation in descriptive retrospective burden of illness studies","volume":"19","author":"Johnston","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.chest.2020.03.010","article-title":"Sample size estimation in clinical research: from randomized controlled trials to observational studies","volume":"158","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"i141","DOI":"10.1093\/noajnl\/vdaa003","article-title":"Quality of life in patients with neurofibromatosis type 1 and 2 in Canada","volume":"2","author":"Hamoy-Jimenez","year":"2020","journal-title":"Neurooncol Adv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","article-title":"Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores","volume":"20","author":"McClure","year":"2017","journal-title":"Value Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.12.012","article-title":"Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach","volume":"15","author":"Hanly","year":"2012","journal-title":"Value Health"},{"key":"ref26","year":"2022"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"ref28","year":"2002"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jval.2018.12.001","article-title":"Future directions in valuing benefits for estimating QALYs: is time up for the EQ-5D?","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"ref31","year":"2019"},{"key":"ref32","year":"2020"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40273-022-01216-9","article-title":"Estimating an EQ-5D-Y-3L value set for China","volume":"40","author":"Yang","year":"2022","journal-title":"PharmacoEconomics"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12955-018-1036-2","article-title":"EQ-5D-5L norms for the urban Chinese population in China","volume":"16","author":"Yang","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1097\/BRS.0000000000003116","article-title":"Responsiveness of EQ-5D youth version 5-level (EQ-5D-5L-Y) and 3-level (EQ-5D-3L-Y) in patients with idiopathic scoliosis","volume":"44","author":"Wong","year":"2019","journal-title":"Spine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1050835","DOI":"10.3389\/fpubh.2022.1050835","article-title":"A cross-sectional study evaluating health-related quality of life of Chinese pediatric patients with hematological malignancies using EQ-5D-Y","volume":"10","author":"Sun","year":"2023","journal-title":"Front Public Health"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10198-021-01307-y","article-title":"Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China","volume":"22","author":"Pei","year":"2021","journal-title":"Eur J Health Econ"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10198-021-01309-w","article-title":"Patient-caregiver agreement and test-retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies","volume":"22","author":"Zhou","year":"2021","journal-title":"Eur J Health Econ"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12955-022-02003-y","article-title":"Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey","volume":"20","author":"Xie","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-024-01672-4","article-title":"Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China","author":"Zhang","year":"2024","journal-title":"Eur J Health Econ"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med Care"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejpn.2023.05.010","article-title":"Health-related quality of life of children with neurofibromatosis type 1: analysis of proxy-rated PedsQL and CHQ questionnaires","volume":"45","author":"Dhaenens","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12955-015-0234-4","article-title":"Adolescent self-report and parent proxy-report of health-related quality of life: an analysis of validity and reliability of PedsQL 4.0 among a sample of Malaysian adolescents and their parents","volume":"13","author":"Kaartina","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-017-2723-2","article-title":"PedsQL Neurofibromatosis type 1 module for children, adolescents and young adults: feasibility, reliability, and validity","volume":"137","author":"Nutakki","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1212\/WNL.0000000000012421","article-title":"Current recommendations for patient-reported outcome measures assessing domains of quality of life in neurofibromatosis clinical trials","volume":"97","author":"Wolters","year":"2021","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s11136-010-9672-y","article-title":"Psychometric properties of the Chinese version of the pediatric quality of life inventory 4.0 generic core scales","volume":"19","author":"Hao","year":"2010","journal-title":"Qual Life Res"},{"key":"ref48","author":"Varni","year":"2023"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1014836921812","article-title":"The PedsQL 4.0 generic Core scales: sensitivity, responsiveness, and impact on clinical decision-making","volume":"25","author":"Varni","year":"2002","journal-title":"J Behav Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jpainsymman.2016.09.007","article-title":"Assessment of burden among family caregivers of people with Parkinson\u2019s disease using the Zarit burden interview","volume":"53","author":"Hagell","year":"2017","journal-title":"J Pain Symptom Manag"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12904-021-00858-4","article-title":"Subjective burdens among informal caregivers of critically ill patients: a cross-sectional study in rural Shandong, China","volume":"20","author":"Fu","year":"2021","journal-title":"BMC Palliat Care"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e0247143","DOI":"10.1371\/journal.pone.0247143","article-title":"Subjective caregiver burden and anxiety in informal caregivers: a systematic review and meta-analysis","volume":"16","author":"Del-Pino-Casado","year":"2021","journal-title":"PLoS One"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1440-1819.2009.02019.x","article-title":"Zarit caregiver burden interview: development, reliability and validity of the Chinese version","volume":"63","author":"Lu","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1017\/S0714980800012484","article-title":"Reliability, validity and reference values of the Zarit burden interview for assessing informal caregivers of community-dwelling older persons with dementia","volume":"19","author":"H\u00e9bert","year":"2000","journal-title":"Can J Aging"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1477-7525-9-103","article-title":"Measuring health-related quality of life in children with cancer living in mainland China: feasibility, reliability and validity of the Chinese mandarin version of PedsQL 4.0 generic core scales and 3.0 cancer module","volume":"9","author":"Ji","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.3390\/ijms22115850","article-title":"Current understanding of neurofibromatosis type 1, 2, and schwannomatosis","volume":"22","author":"Tamura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1054931","DOI":"10.3389\/fpubh.2022.1054931","article-title":"Utility estimations of different health states of patients with type I, II, and III spinal muscular atrophy in China: a mixed approach study with patient and proxy-reported data","volume":"10","author":"Hu","year":"2022","journal-title":"Front Public Health"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e77273","DOI":"10.1371\/journal.pone.0077273","article-title":"Impact of functional constipation on health-related quality of life in preschool children and their families in Xi'an, China","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e56945","DOI":"10.1371\/journal.pone.0056945","article-title":"Health-related quality of life among children with recurrent respiratory tract infections in Xi'an, China","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cns.13473","article-title":"Quality of life in children with tuberous sclerosis complex: a pediatric cohort study","volume":"27","author":"Ding","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejpn.2020.07.014","article-title":"Cognitive functioning and pain interference mediate pain predictive effects on health-related quality of life in pediatric patients with neurofibromatosis type 1","volume":"28","author":"Varni","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/ajmg.a.36466","article-title":"Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis","author":"Merker","year":"2014","journal-title":"Am J Med Genet A"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3238\/arztebl.2013.0432","article-title":"Growing up is hard: mental disorders in adolescence","volume":"110","author":"Herpertz-Dahlmann","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12955-020-01572-0","article-title":"Measuring parent proxy-reported quality of life of 11 rare diseases in children in Zhejiang, China","volume":"18","author":"Gao","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"152","DOI":"10.21307\/sjcapp-2018-014","article-title":"Finnish schoolchildren's perceived health-related quality of life deteriorates remarkably with age","volume":"6","author":"Paakkonen","year":"2018","journal-title":"Scand J Child Adolesc Psychiatr Psychol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/ajmg.a.61197","article-title":"Speech difficulties and patient health communication mediating effects on worry and health-related quality of life in children, adolescents, and young adults with neurofibromatosis type 1","volume":"179","author":"Varni","year":"2019","journal-title":"Am J Med Genet A"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11060-015-1725-1","article-title":"Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature","volume":"122","author":"Vranceanu","year":"2015","journal-title":"J Neuro Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12603-020-1327-2","article-title":"Health-related quality of life and associated factors among oldest-old in China","volume":"24","author":"Chen","year":"2020","journal-title":"J Nutr Health Aging"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/cncr.34003","article-title":"Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study","volume":"128","author":"van Gorp","year":"2022","journal-title":"Cancer"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s11136-019-02167-z","article-title":"Health-related quality of life and perceived health status of Turkish population","volume":"28","author":"Dinc Horasan","year":"2019","journal-title":"Qual Life Res"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.iccn.2020.102829","article-title":"ECMO survivors\u2019 quality of life and needs after discharge: a descriptive, comparative cross-sectional pilot study","volume":"59","author":"Tiedebohl","year":"2020","journal-title":"Intensive Crit Care Nurs"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12877-022-03216-y","article-title":"Exploring the difference between men and women in physical functioning: how do sociodemographic, lifestyle- and health-related determinants contribute?","volume":"22","author":"Sialino","year":"2022","journal-title":"BMC Geriatr"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12955-022-01996-w","article-title":"EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report","volume":"20","author":"Fitriana","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s11136-019-02238-1","article-title":"Psychometric properties of the Japanese version of the EQ-5D-Y by self-report and proxy-report: reliability and construct validity","volume":"28","author":"Shiroiwa","year":"2019","journal-title":"Qual Life Res"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.anpedi.2013.11.028","article-title":"Validity and reliability of the Spanish EQ-5D-Y proxy version","volume":"81","author":"Gusi","year":"2014","journal-title":"An Pediatr"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.jpedsurg.2018.08.036","article-title":"The long-term quality of life outcomes in adolescents with Hirschsprung disease","volume":"53","author":"Sood","year":"2018","journal-title":"J Pediatr Surg"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s11136-015-1002-y","article-title":"Six years beyond pediatric trauma: child and parental ratings of children's health-related quality of life in relation to parental mental health","volume":"24","author":"Sluys","year":"2015","journal-title":"Qual Life Res"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.jpeds.2013.04.037","article-title":"Health related quality of life in patients with biliary atresia surviving with their native liver","volume":"163","author":"Sundaram","year":"2013","journal-title":"J Pediatr"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12955-016-0445-3","article-title":"Health-related quality of life in children with chronic immune thrombocytopenia in China","volume":"14","author":"Zhang","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jpedsurg.2007.12.038","article-title":"Long-term bowel function and quality of life in children with Hirschsprung\u2019s disease","volume":"43","author":"Mills","year":"2008","journal-title":"J Pediatr Surg"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1023\/A:1012253723272","article-title":"Can parents rate their child's health-related quality of life? Results of a systematic review","volume":"10","author":"Eiser","year":"2001","journal-title":"Qual Life Res"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1037\/0033-2909.101.2.213","article-title":"Child\/adolescent behavioral and emotional problems: implications of cross-informant correlations for situational specificity","volume":"101","author":"Achenbach","year":"1987","journal-title":"Psychol Bull"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1023\/A:1008801802877","article-title":"The proxy problem: child report versus parent report in health-related quality of life research","volume":"7","author":"Theunissen","year":"1998","journal-title":"Qual Life Res"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/1346-8138.13902","article-title":"Clinical severity in Japanese patients with neurofibromatosis 1 based on DNB classification","volume":"44","author":"Ehara","year":"2017","journal-title":"J Dermatol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1398803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:12:35Z","timestamp":1724346755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1398803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":85,"alternative-id":["10.3389\/fpubh.2024.1398803"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1398803","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"article-number":"1398803"}}